Braxia Scientific Corp. How can we advance treatment discovery and development in psychiatry targeting cognition? (Session chair: Dr Susannah Murphy)
Where are we with treatment discovery and development in psychiatry as it relates to targeting cognition? What are next steps? What are some promising targets? We are going to describe how research will be conducted with ketamine and psychedelics that integrates machine learning, proof-of-mechanism research and implementation science which will be critical for the impact of any innovative psychedelic on population health.
Compass Pathways
How can subjective experiences (in particular, psychedelic induced experiences) be objectively measured? (Session chair: Prof Philip Cowen)
Psychedelic/psychoactive substances induce unique subjective experiences that unfold upon administration. These experiences are thought be instrumental in mediating the potential efficacy of these substances. How can we correlate objective measures (EEG, fMRI, skin conductance, plasma protein levels etc), with subjective experiences? Might we be able to use these correlations to find biomarkers of efficacy or to better understand the mechanism of drug action?
How can preclinical behavioural studies be designed to optimise translation within the context of screening novel compounds for clinical development? (Session chair: Prof David Bannerman)
Once lead compounds are identified, and basic safety and efficacy signals are obtained, they are ready to be tested in vivo. Animal and human behavioral tests can be used as proof of concept to further inform efficacy and choice of indication for clinical trials. How can we design new or adapt existing behavioral test to maximise translatability to clinical setting? How can maximise the value of behavioral proof of concept designs?
https://braxiascientific.com/news/braxia-scientific-to-discuss-psychiatric-treatment-discovery-and-development-with-oxford-university-researchers-at-aimday-experimental-medicine-in-psychiatry-on-july-7-2021/